ERBB2 and breast carcinoma: ,8 Data from DESTINY-Breast01 supported global approvals of T-DXd for use in adult patients with unresectable or metastatic HER2-positive breast cancer that progressed on two or more prior therapies.9, 10, 11, 12, 13, 14, 15